APRE - CIK 0001781983
Aprea Therapeutics, Inc. (APRE) reported net income of -$12.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$12.60M | +2.8% |
| FY 2024 | -$12.96M | +9.3% |
| FY 2023 | -$14.29M | +87.3% |
| FY 2022 | -$112.66M | -203.4% |
| FY 2021 | -$37.13M | +30.6% |
| FY 2020 | -$53.48M | -90.6% |
| FY 2019 | -$28.06M | -80.7% |
| FY 2018 | -$15.53M | -2.2% |
| FY 2017 |
Aprea Therapeutics, Inc. (APRE) reported net income of -$12.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Aprea Therapeutics, Inc.'s net income grew from -$15.19M to -$12.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$15.19M |
| - |